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Introduction

Summary
Endothelial cells (ECs) are primary targets of glucose-induced
tissue damage. As a result of hyperglycemia, endothelin-1 (ET-1)
is

upregulated

in

organs

affected

by

chronic

diabetic

complications. The objective of the present study was to identify
novel transcriptional mechanisms that influence ET-1 regulation
in diabetes. We carried out the investigation in microvascular ECs
using multiple approaches. ECs were incubated with 5 mM
glucose (NG) or 25 mM glucose (HG) and analyses for DNA
methylation,

histone

methylation,

or

long

non-coding

RNA- mediated regulation of ET-1 mRNA were then performed.
DNA methylation array analyses demonstrated the presence of
hypomethylation in the proximal promoter and 5’ UTR/first exon
regions of EDN1 following HG culture. Further, globally blocking
DNA methylation or histone methylation significantly increased
ET-1 mRNA expressions in both NG and HG-treated HRECs.
While, knocking down the pathogenetic lncRNAs ANRIL, MALAT1,
and

ZFAS1

subsequently

prevented

the

glucose-induced

upregulation of ET-1 transcripts. Based on our past and present
findings, we present a novel paradigm that reveals a complex
web of epigenetic mechanisms regulating glucose-induced
transcription of ET-1. Improving our understanding of such
processes may lead to better targeted therapies.
Key words
ET-1 • Epigenetics • lncRNAs • DNA methylation • Histone
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With the continuous global rise in diabetes
(IDF 2015), the risk for developing glucose-induced
injuries to the microvasculature also remains high. As
a consequence of hyperglycemia, microvascular damage
gives rise to debilitating complications affecting the eyes,
kidneys, and peripheral nerves (Fowler 2011). To
minimize the risk of subsequent diabetes-induced vessel
damage, current therapeutic modalities are comprised of
lifestyle changes and pharmaceutical intervention
(Chawla et al. 2016, Fowler 2011). Although these
therapies may be effective in impeding some progression
of late stage diabetic complications, the presence of
‘metabolic memory’ contributes to unique molecular
alterations that may alter an individual’s response to
treatments (Roberto et al. 2017). Epigenetic mechanisms
comprise the ‘metabolic memory’ phenomenon and
identification of these mechanisms would expand current
therapeutic modalities, allowing for the development of
targeted treatment strategies.
Modifications to the epigenome influence gene
expression without changing the underlying nucleotide
sequence (Weinhold 2006). DNA methylation, histone
modifications, and the activity of non-coding RNAs are
examples of such epigenetic mechanisms that are
involved in metabolic memory (Biswas and Chakrabarti
2017). The identification of these processes have been
made evident by high throughput genomic technologies,
however new questions arise with respect to our current
understanding of the documented mechanistic properties
for pro-inflammatory markers.
Endothelin-1 (ET-1) is a prominent peptide in

PHYSIOLOGICAL RESEARCH • ISSN 0862-8408 (print) • ISSN 1802-9973 (online)
 2018 Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
Fax +420 241 062 164, e-mail: physres@fgu.cas.cz, www.biomed.cas.cz/physiolres

S116

Biswas et al.

diabetes that has been well documented within the last
three decades. As previously demonstrated by our
laboratory and others, aberrations in metabolic pathways
can heighten the production of ET-1 and subsequently
allow for an increased pathologic state in various diabetic
complications (Chen et al. 2000, Chakrabarti et al. 1998,
Takahashi et al. 1990). Using such knowledge and
information from ligand-binding studies, drugs were
developed to target the ET-1 receptors, in order to mitigate
cellular dysfunction and other effects in diabetic
complications (Sasser et al. 2007, Kohan and Pollock
2013). Despite the promising results for endothelin
receptor antagonists in animal models, investigators
discovered that there were adverse, undesirable and
heterogeneous responses present among numerous patients
using these drugs, suggesting that there are alternative
mechanisms implicated in ET-1 regulation (Remuzzi et al.
2002). As the mechanistic impact of epigenetic machinery
on ET-1 production still remains unclear, further
characterization is warranted to understand such a process.
In this study, we examined the roles of DNA
methylation, histone methylation, and long non-coding
RNAs (lncRNAs) on ET-1 regulation in retinal
microvascular endothelial cells (HRECs). We performed
a DNA methylation array to identify whether unique
methylation patterns exist across the ET-1 gene (EDN1)
after high glucose (HG) incubation. To further follow-up
our findings from the methylation array, we employed
a global DNA methylation inhibitor in HRECs to
determine the impact of DNA methyltransferases on ET-1
regulation. Next, we subjected HRECs to a histone
methylation inhibitor to understand the influence of histone
methyltransferases on ET-1 mRNA production. Moreover,
based on our previous lncRNA microarray analysis
(Thomas et al. 2017), we selected three prominent
HG-induced upregulated lncRNAs and silenced these
lncRNAs to determine the effects on ET-1. We then
collated our previous and current findings to present
an all-inclusive epigenetic paradigm for ET-1 regulation.

Materials and Methods
Cell culture
Endothelial dysfunction is one of the earliest
pathological features during chronic hyperglycemia
(Alder et al. 1997). Hence, we used HRECs (Olaf
Pharmaceuticals; MA, USA) for our experiments. Such
experimental conditions have been previously described
(Puthanveetil et al. 2015, Thomas et al. 2017, Ruiz et al.
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2015, Khan et al. 2004) and all cell culture reagents were
purchased from Sigma (Oakville, ON, CAN). Based on
our previous findings, the 48-h time point was selected
for our in vitro experiments. All experiments were
independently repeated at least three times and performed
with six replicates, unless specified.
EDN1 CpG DNA methylation analysis
The Illumina Infinium MethylationEPIC
BeadChip array (Illumina; CA, USA) was used to
identify differential methylation patterns of CpG sites
across the EDN1 gene in HRECs incubated in 5 mM
glucose (NG, mimicking euglycemia) and in 25 mM
glucose (HG, mimicking hyperglycemia). Genomic DNA
was extracted from HRECs after 48 h of glucose culture
and 1 μg of DNA was used for bisulfite conversion using
the EZ DNA Methylation Kit (Zymo Research; CA,
USA). The HiScan System (Illumina; CA, USA) was
used to obtain the array readout and the methylated and
unmethylated signal intensity data were then imported
into R 3.4.0 for analysis. Normalization was performed
using Illumina normalization method with background
correction using the minfi package. Probes with detection
P-value >0.01 were excluded from the downstream
analyses. In addition, probes known to contain SNPs at
the CpG interrogation or the single nucleotide extension
were removed. Methylation level for each probe was
measured as a beta value (β-value), calculated from the
ratio of the methylated signals versus the total sum
of unmethylated and methylated signals, ranging
between 0 (no methylation) and 1 (full methylation).
Three independent samples were used per group.
3-Deazaneplanocin A (DZNep) and 5-Aza-2’-deoxycytidine
(5-aza-dC)
In order to understand the impact of histone and
DNA methylation inhibition on ET-1, we used
pharmacological inhibitors that globally blocked the
methylation process. Therefore, based on previous
literature, 1 h pre-treatment of either 5 μM of DZNep
(Cayman Chemical; MI, USA) or 5-aza-dC (Sigma; STL,
USA) was applied to HRECs prior to addition of
D-glucose (Ruiz et al. 2015, Thomas et al. 2017, Xie et
al. 2014). DZNep or 5-aza-dC-treated HRECs, and their
respective controls, were collected at 48 h for further
analyses.
SiRNA-mediated transfection
HRECs were initially transfected with either two
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pre-designed siRNAs targeting human ANRIL (antisense
RNA to INK4 locus), MALAT1 (metastasis-associated
lung adenocarcinoma transcript 1), or ZFAS1 (zinc finger
antisense 1), or scrambled siRNA (catalog number:
AM4635, Life Technologies; CA, USA) using
Lipofectamine 2000 (Invitrogen; ON, CA) and
Opti-MEM (Life Technologies; CA, USA). Details
regarding the lipofectamine-mediated transfection
protocol can be found in our previous studies (Ruiz et al.
2015, Thomas et al. 2017). Following confirmation of
knockdown by RT-qPCR, the siRNA sequences with the
best knockdown were selected for this study: ANRIL
(Lincode CDKN2B-AS1; catalog number: R-188105-000005, Dharmacon; IL, USA), MALAT1 (catalog number:
n272233, Life Technologies; CA, USA), and ZFAS1
(catalog number: n271357, Life Technologies; CA, USA).
Enzyme-Linked Immunosorbent Assay (ELISA)
ET-1 protein levels were determined from cell
supernatants of DZNep or 5-aza-dC-treated HRECs using
the ET-1 Quantikine ELISA kit (R&D Systems; MP,
USA). Concentrations were first quantified using the
BCA protein assay kit (Pierce; IL, USA) and 100 μg of
protein was equally used for each sample according
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to the manufacturer’s instructions. The Multiskan FC
Microplate Photometer (Thermo Fisher Scientific; MA,
USA) determined the optical density for each well at
450 nm and corrected using 568 nm.
RNA isolation and quantitative Real-Time Polymerase
Chain Reaction (RT-qPCR)
As previously described, the TRIzol reagent
(Invitrogen; Burlington, ON, CAN) was used to extract
total RNA and a spectrophotometer (260 nm; Gene
Quant, Pharmacia Biotech, USA) was utilized to quantify
RNA concentrations (Ruiz et al. 2015, Thomas et al.
2017, Khan et al. 2004, Puthanveetil et al. 2015).
A high-capacity complementary DNA (cDNA) kit
(Applied Biosystems; Burlington, ON, CAN) was then
employed to reverse transcribe 1 μg of total RNA to
cDNA. Next, in combination with SYBR-green master
mix (Clontech, CA, USA) and specific target gene
primers (Sigma; Table 1), cDNA was amplified in the
LightCycler 96 System (Roche Diagnostics, QC, CA) to
detect RNA expression. Expression levels were further
calculated by the relative standard curve method using
β-actin as internal control for normalization.

Table 1. Oligonucleotide sequences used for RT-qPCR.

Target gene

Oligonucleotide sequence (5´→3´)

β-actin (Homo)

Forward: CCTCTATGCCAACACAGTGC
Reverse: CATCGTACTCCTGCTTGCTG
Forward: AAGCCCTCCAGAGAGCGTTAT
Reverse: CCGAAGGTCTGTCTGTCACCAATGT

Endothelin-1 (Homo)

Statistical analysis
All statistical tests were performed using
GraphPad Prism 7 (GraphPad, CA, USA). Data are
expressed as mean ± SEM. Student’s t-test or 1-way
ANOVA, followed by Tukey’s post hoc test, were used
as appropriate. Differences with a P value below 0.05
were considered significant.

Results
Transient HG treatment results in hypomethylation of
CpG sites in the proximal promoter regions of EDN1
Following our methylation profiling of NG and
HG-treated HRECs, we exclusively selected the CpG
sites that spanned across EDN1, which corresponded to

12 probes (Supplementary File S1). All of the probes
were placed in the ‘Open Sea’ category, since the array
did not detect a CpG island (defined as regions that have
a GC content greater than 50 % and are greater than
200 base pairs in length; Gardiner-Garden and Frommer
1987) in the EDN1 region, which was also confirmed by
the UCSC Human Genome Browser (University of
California, Santa Cruz, CA, USA; Fig. 1A). Using
annotations derived by Illumina, we further categorized
the probes based on functional location relative to the
gene region: TSS1500 (region that is -200 to -1,500
nucleotides upstream from the transcription start site),
TSS200 (the region from -200 nucleotides upstream to
the transcription start site itself), 5’ UTR (can include the
region through the first exon), gene body, and 3’ UTR.
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Fig. 1. CpG sites in specific regions of EDN1 are hypomethylated following high glucose treatment in vitro. A) Information on the
human EDN1 gene annotated from the UCSC database. EDN1 is located on chromosome 6 and spans from the nucleotide positions 12,
289, 311 to 12, 296, 209 (6899 nucleotides in size; Kent et al. 2002). B) A heat map depicting the methylation intensity (in ß-values) of
specific CpG dinucleotides across EDN1 in HRECs following 48 h of NG or HG culture. The Illumina methylation array indicates that
a ß-value of 1 suggests complete methylation at the interrogated site, while a value of 0 indicates no methylation. C) A bar graph
categorizing the methylation intensities of probes based on gene region. The proximal promoter and 5’ UTR/first exon regions
demonstrated CpG hypomethylation following HG treatment (data expressed as average ß-value per region; N=3 independent samples
for each NG or HG group). * denotes a significant reduction in methylation following HG treatment.

Analyzing the EDN1 regions, there were four probes for
TSS1500, five probes for TSS200, one probe for 5’ UTR,
one probe for gene body, and one probe for 3’ UTR.
According to our array readout, nearly 58 % of CpG sites
were hypomethylated following 48 h of HG treatment
(Fig. 1B). In addition, a substantial number of these
hypomethylated CpG sites were predominantly located in
the TSS200 region of EDN1, while a hypomethylated
CpG site was also detected in both TSS1500 and 5’ UTR
regions (Fig. 1C). Despite the overall methylation
intensities between the NG and HG groups being low for
each gene region (0≤β-value≥0.119; a value of 0 indicates
no methylation, while a value of 1 indicates maximal
methylation), the percentage of methylation further
reduced at CpG sites in the proximal promoter and
promoter regions of EDN1 following high glucose
treatment.

Global inhibition of DNA methyltransferases increases
ET-1 expression
To further investigate the impact of DNA
methylation on EDN1 regulation, we administered
a DNA demethylating agent in HRECs prior to glucose
treatment. Following the global inhibition of DNA
methyltransferases, we subsequently analyzed ET-1
mRNA (the main product of EDN1 transcription) and
protein expressions using RT-qPCR and ELISA,
respectively. Interestingly, 5’-aza-dC administration
significantly augmented both ET-1 RNA and protein
expressions in NG and HG-treated HRECs compared to
controls (Figs 2A and 2C). Among the groups analyzed,
HRECs that were cultured with NG and 5’-aza-dC
demonstrated comparable ET-1 RNA and protein
expression levels to HRECs cultured solely in
HG-suggesting the importance of DNA methyltransferases
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in governing the transcriptional activity of EDN1.
Collectively, both of our DNA methylation
experiments indicate that hyperglycemic environments
can greatly impact DNA methylation patterns in EDN1
and its transcriptional products, which can ultimately
govern translation of the final protein products.
Histone methylation is important in ET-1 regulation
Following demonstration of DNA methylation’s
impact on ET-1, we investigated the role of histone
methylation on ET-1 mRNA and protein expressions.
Therefore, prior to glucose treatment, we subjected HRECs
to a global histone methylation inhibitor and subsequently
analyzed ET-1 mRNA and protein levels. Similar to the
trends observed in our 5’-aza-dC experiment, DZNep
pre-treatment significantly upregulated both ET-1 RNA
and protein expressions in NG and HG-treated HRECs
(Figs 2B and 2D). Following pharmacologic inhibition of
histone methylation, the sharp induction of ET-1
expressions in both NG and HG-treated HRECs alludes to
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the regulatory capabilities of histone methyltransferases on
ET-1 transcription and translation.
lncRNAs regulate ET-1 expression in hyperglycemia
Compared to scrambled controls, approximately
70 %, 75 %, and 90 % knockdown activity was observed
in HRECs following siANRIL, siMALAT1, and siZFAS1
treatments, respectively (data not shown). Interestingly,
the siRNA-directed inhibition of ANRIL, MALAT1, or
ZFAS1 also significantly reduced ET-1 mRNA in
HG-treated HRECs (Fig. 3). More specifically, when
compared to scrambled controls, ANRIL knockdown
contributed to the greatest reduction of ET-1 expression
in HG-treated HRECs (~75 %; Fig. 3A); while, siMALAT1
(Fig. 3B) and siZFAS1 (Fig. 3C) demonstrated comparable
levels of ET-1 mRNA reduction (~37-42 %) in HG-treated
HRECs. Taken together, the findings observed from our
knockdown experiments suggest that pathogenetic
lncRNAs can also influence glucose-induced upregulation
of ET-1 in microvascular endothelial cells (ECs).

Fig. 2. Global inhibition of DNA or histone methylation significantly increases ET-1 expressions in HRECs. RT-qPCR findings indicate that
A) 5-aza-dC treatment increases ET-1 expressions in NG or HG-treated HRECs, B) DZNep treatments also showed similar patterns of
ET-1 upregulation (data expressed as a ratio to β-actin (mean ± SEM); normalized to NG; * P<0.05, *** P<0.001, and **** P<0.0001
compared to NG or HG; and N=6 from three independent experiments and performed in triplicates). C, D) ELISAs for ET-1
demonstrated elevated ET-1 protein levels (expressed as pg/ml) following 5-aza-dC or DZNep treatment (* P<0.05, *** P<0.001, and
**** P<0.0001 compared to NG or HG; and N=6 for each group).
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Fig. 3. ANRIL, MALAT1, and ZFAS1 regulate glucose-induced production of ET-1 mRNA in vitro. RT-qPCR analyses indicating that
A) siANRIL, B) siMALAT1, and C) siZFAS1 caused significant reductions in the glucose-induced upregulation of ET-1 transcripts (data
expressed as a ratio to β-actin (mean ± SEM); normalized to SCR NG; * P<0.05, ** P<0.01, *** P<0.001, and n.s., not significant
compared to SCR NG or SCR HG; and N=6 from three independent experiments and performed in triplicates).

Discussion
When a chronic hyperglycemic environment
jeopardizes the integrity of the endothelium, the risk of
advancement to severe diabetic microvascular
complications dramatically heightens. ECs are one of the
earliest cells to undergo dysfunction in diabetes,
contributing to disease progression (Hadi and Suwaidi
2007). During the development of endothelial
dysfunction, one well-documented characteristic is the
heightened production and activity of ET-1 (Iglarz and
Clozel 2007, Schneider et al. 2002).
Located on chromosome 6, the human EDN1
generates a 2.8-kb transcript that encodes for the pre-proET-1 protein (Yanagisawa et al. 1988). Once pre-proET-1 is generated, the 212-amino-acid protein then
undergoes a series of proteolytic modifications to
ultimately produce the mature ET-1 peptide (Yanagisawa
et al. 1988). Although post-translational mechanisms are
moderating ET-1 processing, large bodies of scientific
reports indicate that ET-1 bioavailability is mainly
directed by transcriptional regulation (Chakrabarti et al.
1998, Chen et al. 2010, Inoue et al. 1989, Stow et al.
2009, Oliver et al. 1991). In fact, the 6.8-kb spanning

mammalian EDN1 can be transcriptionally governed by
a plethora of transcription factors, which can include
hypoxia inducible factor-1, NF-κB, activator protein-1,
GATA-2, and c-Myc (Kawana et al. 1995, Quehenberger
et al. 2000, Shichiri et al. 1997, Yamashita et al. 2001).
Despite the well-documented literature on the various
stimuli driving EDN1 transcription, recognizing and
incorporating novel regulatory mechanisms, such as
epigenetic regulation, into the current ET-1 signaling
paradigm will allow for improved understanding and
exploration of innovative therapeutics.
Technological advancements in next-generation
sequencing have allowed for the identification of
genome-wide DNA methylation patterns, which have
critical implications in disease pathogenesis. Based on
our DNA methylation array, we were able to develop
significant insights into the glucose-induced methylation
patterns present in the regulatory regions of EDN1.
Specifically, in HRECs, transient high glucose exposure
sufficiently evoked hypomethylation in the proximal
promoter and 5’ UTR/first exon regions of EDN1.
In association, HG-treated HRECs also demonstrated
a significant upregulation of ET-1 mRNA and protein at
the 48-h mark. Our findings, together with previous
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reports by Han et al. (2011) and Feinberg and Vogelstein
(1983), highlight the importance of reduced methylation
at CpG dinucleotides in the regulatory regions of actively
transcribed genes. In fact, hypomethylated CpG sites in
the promoter regions of an active gene provide a greater
degree of accessibility for transcription factors, which
will then facilitate transcription (Deaton and Bird 2011,
Eckhardt et al. 2006). Moreover, Vallender and Lahn
(2006) have previously indicated that hypermethylation
of CpG regions near intron 1 in Edn1 blocks the binding
site for the Sp1 transcription factor, which may contribute
to Edn1 silencing in mice fibroblasts (Vallender and Lahn
2006).
Despite the presence of differential CpG
methylation patterns across EDN1 between NG and
HG-treated HRECs, the administration of a global DNA
demethylating agent resulted in significant inductions of
ET-1 mRNA and protein in both HREC groups. This data
is in keeping with past reports in which similar trends for
ET-1 expressions were observed in fibroblasts (Vallender
and Lahn 2006) and 1833-bone metastatic cells
(Matteucci et al. 2013) following the complete inhibition
of DNA methylation. These findings, along with our
study, suggest that DNA methyltransferases have
a critical role in regulating the transcriptional status of
EDN1 and that pathological stimuli may be capable of
altering the DNA methylating properties of these
enzymes in the EDN1 region.
In the context of histone modifications, globally
inhibiting histone methylation provoked significant
elevations of ET-1 mRNA and protein in HRECs cultured
with NG and HG. The profound influence of histone
methylation on EDN1 transcriptional activity has been
previously documented in renal epithelial cells, where
aldosterone treatment induced specific histone
conformation changes that maintained active transcription
in the EDN1 promoter (Stow et al. 2009). Although
chronic hyperglycemic environments can facilitate
chromatin remodeling by histone methylation, histone
acetylation can also significantly contribute to chromatin
state dynamics. Former studies from our laboratory have
indicated that the upregulation of histone acetyltransferase
p300 can cause increased EDN1 promoter activity (Chen
et al. 2009), reduced expression of the class II histone
deacetylase SIRT1 (Mortuza et al. 2015), and increased
expressions of ET-1 transcripts, extracellular matrix
(ECM) proteins and vasoactive factors (Chen et al. 2009,
Feng et al. 2011). Collectively, our past and current
findings demonstrate that pathologies like diabetes can
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cause unique alterations in histone modification patterns,
which may ultimately enhance EDN1 transcriptional
activity and contribute to elevated ET-1 protein levels.
With lncRNAs greatly influencing the epigenetic
landscape, we knocked down three pathogenetic glucoseinduced lncRNAs in HRECs in order to determine the
impact of lncRNAs on ET-1 transcript expression.
Following siRNA-mediated knockdown of ANRIL,
MALAT1, and ZFAS1, significant reductions in ET-1
mRNA levels were observed. These findings are
consistent with the notion that lncRNAs can alter mRNA
transcription by controlling chromatin structure,
transcription factors, nuclear organization, or specific
protein complexes (Kugel and Goodrich 2013). To
further support these notions, we have previously shown
that ANRIL can regulate VEGF (vascular endothelial
growth factor) through its direct interactions with p300
and PRC2 (polycomb repressive complex 2; a histone
methyltransferase) in HRECs (Thomas et al. 2017). Such
a mechanistic study is warranted for ET-1, so that the
direct relationship between epigenetic mediator proteins
and EDN1 can be confirmed in a diabetic context.
Moreover, we have previously demonstrated the importance
of microRNAs (miRNAs) 1 and 320 in ET-1 regulation
(Feng et al. 2014, Feng and Chakrabarti 2012), miR-200b
in mediating PRC2 and p300 activities (Ruiz et al. 2015,
McArthur et al. 2011), and miR-146a impacting ECM
proteins (Feng et al. 2011), inflammatory cytokines
(Chen et al. 2017), and endothelial-to-mesenchymal
transitioning (Cao et al. 2014). Therefore, based on our
past and current findings, we collated the pertinent
information and developed an epigenetic paradigm for
ET-1 regulation (Fig. 4).
Since we have reported alterations in ET-1
expression following global inhibition of histone and
DNA methylation, and lncRNA knockdown, it is
important to note that these changes may reflect a more
widespread phenomenon extending to other genes. As
well, the alterations observed in our experiments are
based on a single time point, which only provides
a snapshot of the epigenetic phenomena on ET-1
regulation. We understand that these are limitations of
our study and additional work is warranted to look into
additional time points and identify other key genes
implicated in this intricate network. Future experiments
should also investigate the impact of epigenetic
mechanisms on ET receptors, as these receptors play an
important role in eliciting the physiological responses of
ET-1 upon binding.
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Fig. 4. An illustration depicting the proposed epigenetic paradigm underlying ET-1 regulation in microvascular endothelial cells in
diabetes. Based on our previous and current findings, we propose this epigenetic model in which histone modifications,
DNA methylation, miRNAs, and lncRNAs can possibly influence EDN1 transcriptional activity and ultimately ET-1 RNA and protein levels.
GDP, guanosine diphosphate; GTP, guanosine triphosphate; lncRNA, long non-coding RNA; miRs, microRNAs; p300, histone
acetyltransferase; H2A-H4, histones; RNA Pol. II, RNA polymerase II; and A, acetylation.

Incorporation of the emerging regulatory
mechanisms into the previously understood paradigm of
ET-1 signaling becomes imperative in the development of
novel ET-1-based therapeutics. Although the findings
from our study shed novel insights into the epigenetic
influence on ET-1 regulation, further mechanistic studies
are necessary to elucidate the direct relationship between
epigenetic mediator proteins and ET-1 in the diabetes
context.
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